Emergent BioSolutions
Gaithersburg, United StatesFounded 1998Industry
Emergent BioSolutions develops and supplies medical countermeasures for anthrax, smallpox, chemical and radiological threats. CBRNE-relevant work is a notable product line according to its website.
What it does
Threats covered
Profile
Emergent BioSolutions began in 1998 as BioPort, supplying the BioThrax anthrax vaccine to the US military, and later became Emergent. BioThrax is licensed for pre- and post-exposure anthrax prophylaxis, and CYFENDUS, a two-dose post-exposure anthrax vaccine, was approved in 2023.
More profile
In 2025 the US Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority, awarded a 30 million dollar CYFENDUS contract modification, and in 2026 it awarded another modification of about 24 million dollars. Emergent acquired NARCAN naloxone nasal spray in 2018 and added commercial rights to the KLOXXADO naloxone product in 2025.
A Washington Post investigation in 2020 examined the billions in government funding it received for biowarfare preparedness.
Ownership
Publicly listed on the NYSE (EBS)
Parent: none (publicly listed) (checked)
Sources (5)
- https://www.emergentbiosolutions.com/our-company/
- https://www.washingtonpost.com/investigations/before-the-pandemic-top-contractor-received-billions-from-government-to-help-prepare-the-nation-for-biowarfare/2020/06/17/38d9ad3a-a41b-11ea-8681-7d471bf20207_story.html
- https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm
- https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/ebs-20250902.htm
- https://investors.emergentbiosolutions.com/news/news-details/2026/Emergent-BioSolutions-Awarded-Contract-Modification-Valued-at-Approximately-24-Million-for-CYFENDUS-Anthrax-Vaccine-Adsorbed-Adjuvanted/default.aspx
Not verified or not found
- Headquarters city: Gaithersburg, Maryland is from general knowledge and was not in the sources read; confirm in the 10-K.
- Botulism and smallpox product details: not read in these sources.
- Total government funding: not stated.
Questions
What does Emergent BioSolutions do?
Emergent BioSolutions develops and supplies medical countermeasures for anthrax, smallpox, chemical and radiological threats. CBRNE-relevant work is a notable product line according to its website.
Where is Emergent BioSolutions based?
HQ (as found): Gaithersburg. HQ country: US.
Who owns Emergent BioSolutions?
Publicly listed on the NYSE (EBS). Parent: none (publicly listed) (checked)
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction